COGT
Price
$36.39
Change
-$0.89 (-2.39%)
Updated
Feb 4, 02:32 PM (EDT)
Capitalization
5.73B
41 days until earnings call
Intraday BUY SELL Signals
CYTOF
Price
$0.30
Change
-$0.11 (-26.83%)
Updated
Dec 19 closing price
Capitalization
628.7K
Intraday BUY SELL Signals
Interact to see
Advertisement

COGT vs CYTOF

Header iconCOGT vs CYTOF Comparison
Open Charts COGT vs CYTOFBanner chart's image
Cogent Biosciences
Price$36.39
Change-$0.89 (-2.39%)
Volume$165
Capitalization5.73B
Altamira Therapeutics
Price$0.30
Change-$0.11 (-26.83%)
Volume$830.27K
Capitalization628.7K
COGT vs CYTOF Comparison Chart in %
COGT
Daily Signal:
Gain/Loss:
CYTOF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
COGT vs. CYTOF commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a Hold and CYTOF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (COGT: $37.28 vs. CYTOF: $0.11)
Brand notoriety: COGT and CYTOF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: COGT: 41% vs. CYTOF: 10%
Market capitalization -- COGT: $5.73B vs. CYTOF: $628.7K
COGT [@Biotechnology] is valued at $5.73B. CYTOF’s [@Biotechnology] market capitalization is $628.7K. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COGT’s FA Score shows that 1 FA rating(s) are green whileCYTOF’s FA Score has 1 green FA rating(s).

  • COGT’s FA Score: 1 green, 4 red.
  • CYTOF’s FA Score: 1 green, 4 red.
According to our system of comparison, both COGT and CYTOF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COGT’s TA Score shows that 3 TA indicator(s) are bullish while CYTOF’s TA Score has 4 bullish TA indicator(s).

  • COGT’s TA Score: 3 bullish, 6 bearish.
  • CYTOF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CYTOF is a better buy in the short-term than COGT.

Price Growth

COGT (@Biotechnology) experienced а -3.19% price change this week, while CYTOF (@Biotechnology) price change was -15.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

COGT is expected to report earnings on Mar 17, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COGT($5.73B) has a higher market cap than CYTOF($629K). CYTOF YTD gains are higher at: 18.932 vs. COGT (4.955). CYTOF has higher annual earnings (EBITDA): -5.46M vs. COGT (-308.13M). COGT has more cash in the bank: 391M vs. CYTOF (3.76K). CYTOF has less debt than COGT: CYTOF (790K) vs COGT (60.6M). COGT (0) and CYTOF (0) have equivalent revenues.
COGTCYTOFCOGT / CYTOF
Capitalization5.73B629K910,334%
EBITDA-308.13M-5.46M5,645%
Gain YTD4.95518.93226%
P/E RatioN/A0.05-
Revenue00-
Total Cash391M3.76K10,412,783%
Total Debt60.6M790K7,671%
FUNDAMENTALS RATINGS
COGT vs CYTOF: Fundamental Ratings
COGT
CYTOF
OUTLOOK RATING
1..100
6934
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
25100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3448
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTOF's Valuation (8) in the Biotechnology industry is significantly better than the same rating for COGT (81) in the Miscellaneous industry. This means that CYTOF’s stock grew significantly faster than COGT’s over the last 12 months.

COGT's Profit vs Risk Rating (25) in the Miscellaneous industry is significantly better than the same rating for CYTOF (100) in the Biotechnology industry. This means that COGT’s stock grew significantly faster than CYTOF’s over the last 12 months.

COGT's SMR Rating (99) in the Miscellaneous industry is in the same range as CYTOF (99) in the Biotechnology industry. This means that COGT’s stock grew similarly to CYTOF’s over the last 12 months.

COGT's Price Growth Rating (34) in the Miscellaneous industry is in the same range as CYTOF (48) in the Biotechnology industry. This means that COGT’s stock grew similarly to CYTOF’s over the last 12 months.

CYTOF's P/E Growth Rating (99) in the Biotechnology industry is in the same range as COGT (100) in the Miscellaneous industry. This means that CYTOF’s stock grew similarly to COGT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COGTCYTOF
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
COGT
Daily Signal:
Gain/Loss:
CYTOF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UPMMX53.962.32
+4.49%
Victory Precious Metals & Minerals Cl A
MDVSX8.750.09
+1.04%
MassMutual Diversified Value R5
MELSX17.780.17
+0.97%
Morgan Stanley Inst EMkts Ldrs R6
AEPFX63.77-0.06
-0.09%
American Funds EUPAC F2
DISYX21.87-0.39
-1.75%
BNY Mellon International Stock Fund Y

COGT and

Correlation & Price change

A.I.dvisor indicates that over the last year, COGT has been loosely correlated with SPHDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if COGT jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COGT
1D Price
Change %
COGT100%
-1.79%
SPHDF - COGT
63%
Loosely correlated
N/A
NUVL - COGT
52%
Loosely correlated
+2.12%
IDYA - COGT
50%
Loosely correlated
+0.50%
XNCR - COGT
47%
Loosely correlated
-0.99%
SYRE - COGT
47%
Loosely correlated
+1.65%
More

CYTOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTOF has been loosely correlated with CMND. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTOF jumps, then CMND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTOF
1D Price
Change %
CYTOF100%
N/A
CMND - CYTOF
56%
Loosely correlated
-5.83%
COGT - CYTOF
40%
Loosely correlated
-1.79%
SPHDF - CYTOF
35%
Loosely correlated
N/A
VTVT - CYTOF
29%
Poorly correlated
+7.52%
VERU - CYTOF
28%
Poorly correlated
-0.39%
More